Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 80-70-6 Chemical Structure| 80-70-6

Structure of 80-70-6

Chemical Structure| 80-70-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 80-70-6 ]

CAS No. :80-70-6
Formula : C5H13N3
M.W : 115.18
SMILES Code : CN(C(N(C)C)=N)C
MDL No. :MFCD00008323
InChI Key :KYVBNYUBXIEUFW-UHFFFAOYSA-N
Pubchem ID :66460

Safety of [ 80-70-6 ]

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H225-H302-H314
Precautionary Statements:P280-P305+P351+P338-P310
Class:8(3)
UN#:2920
Packing Group:

Computational Chemistry of [ 80-70-6 ] Show Less

Physicochemical Properties

Num. heavy atoms 8
Num. arom. heavy atoms 0
Fraction Csp3 0.8
Num. rotatable bonds 2
Num. H-bond acceptors 1.0
Num. H-bond donors 1.0
Molar Refractivity 35.53
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

30.33 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.42
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.41
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.04
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.42
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.06
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.25

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-0.68
Solubility 24.0 mg/ml ; 0.209 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-0.61
Solubility 28.0 mg/ml ; 0.243 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.14
Solubility 83.6 mg/ml ; 0.726 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.71 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

2.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.15

Application In Synthesis of [ 80-70-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 80-70-6 ]

[ 80-70-6 ] Synthesis Path-Downstream   1~7

  • 1
  • [ 342-25-6 ]
  • [ 80-70-6 ]
  • [ 446018-27-5 ]
  • 2
  • [ 3240-35-5 ]
  • rac.-N-[2-chloro-4-[[(3-methoxymethoxybenzyl) amino]carbonyl]benzoyl]-2-(dimethoxyphosphinyl)glycine methyl ester [ No CAS ]
  • [ 80-70-6 ]
  • (Z)-3-(4-aminosulfonylphenyl)-2-[[2-chloro-4-[[(3-methoxymethoxybenzyl)amino]carbonyl]benzoyl]amino]propenoic acid methyl ester [ No CAS ]
YieldReaction ConditionsOperation in experiment
In 1,2-dimethoxyethane; Preparation of (Z)-3-(4-aminosulfonylphenyl)-2-[[2-chloro-4-[[(3-hydroxybenzyl)amino]carbonyl]benzoyl]amino]propenoic Acid 1,1,3,3-Tetramethylguanidine (0.046 g, 0.40 mmol) was added to a solution of rac.-N-[2-chloro-4-[[(3-methoxymethoxybenzyl)amino]carbonyl]benzoyl]-2-(dimethoxyphosphinyl)glycine methyl ester (Example 142; 0.047 g, 0.10 mmol) and 4-formylbenzenesulfonamide (lit.: Van Es, T.; Staskun, B. Organic Syntheses 1971, 51, 20-23; 0.019 g, 0.10 mmol) in DME (4 mL). The solution was stirred at room temperature for 20 h and then was poured into water (25 mL). The aqueous layer was extracted with ethyl acetate and the organic layers were dried (Na2SO4), filtered and evaporated to give crude (Z)-3-(4-aminosulfonylphenyl)-2-[[2-chloro-4-[[(3-methoxymethoxybenzyl)amino]carbonyl]benzoyl]amino]propenoic acid methyl ester.
  • 3
  • [ 81131-70-6 ]
  • [ 80-70-6 ]
  • [ 1159685-33-2 ]
YieldReaction ConditionsOperation in experiment
In ethyl acetate; at 20 - 50℃; for 1h;Product distribution / selectivity; An aqueous solution (500 ml) comprising pravastatin sodium (31.25 g) was extracted with ethyl acetate (500 ml) at pH 4. The organic phase was dried on MgSO4, filtered and the filter was washed with ethyl acetate until 500 ml of filtrate was obtained (solution 1 ). a) A solution of TMG (0.71 ml, 5.6 mmol) in ethyl acetate (10 ml) was added dropwise to 40 ml of solution 1 (5.6 mmol pravastatin) at room temperature after which pravastatin TMG salt precipitated as an oil. b) Experiment a) was repeated however 40 ml of solution 1 was diluted with ethanol (2 ml); again pravastatin TMG salt precipitated as an oil. c) Experiment a) was repeated however 40 ml of solution 1 was diluted with ethanol (4 ml) and after addition the mixture was cooled until pravastatin TMG salt precipitated as an oil. d) Solution 1 (40 ml, 5.6 mmol pravastatin) was added in 1 h at 5O0C to a solution of TMG (0.71 ml, 5.6 mmol) in ethyl acetate (10 ml) and after addition the mixture was cooled to room temperature; pravastatin TMG salt precipitated as an oil. e) Experiment d) was repeated with ethanol admixed with the TMG ethyl acetate solution. The same results as under d) were obtained with concentrations of ethanol in the solution of TMG in ethyl acetate of 2.5%, 20% and 40%.
In ethanol; ethyl acetate; at 20℃;Product distribution / selectivity; An aqueous solution (500 ml) comprising pravastatin sodium (31.25 g) was extracted with ethyl acetate (500 ml) at pH 4. The organic phase was dried on MgSO4, filtered and the filter was washed with ethyl acetate until 500 ml of filtrate was obtained (solution 1 ). a) A solution of TMG (0.71 ml, 5.6 mmol) in ethyl acetate (10 ml) was added dropwise to 40 ml of solution 1 (5.6 mmol pravastatin) at room temperature after which pravastatin TMG salt precipitated as an oil. b) Experiment a) was repeated however 40 ml of solution 1 was diluted with ethanol (2 ml); again pravastatin TMG salt precipitated as an oil. c) Experiment a) was repeated however 40 ml of solution 1 was diluted with ethanol (4 ml) and after addition the mixture was cooled until pravastatin TMG salt precipitated as an oil. d) Solution 1 (40 ml, 5.6 mmol pravastatin) was added in 1 h at 5O0C to a solution of TMG (0.71 ml, 5.6 mmol) in ethyl acetate (10 ml) and after addition the mixture was cooled to room temperature; pravastatin TMG salt precipitated as an oil. e) Experiment d) was repeated with ethanol admixed with the TMG ethyl acetate solution. The same results as under d) were obtained with concentrations of ethanol in the solution of TMG in ethyl acetate of 2.5%, 20% and 40%.
  • 4
  • [ 926-39-6 ]
  • [ 98769-72-3 ]
  • [ 80-70-6 ]
  • [ 1250978-71-2 ]
  • C22H31N3O3*H(1+) [ No CAS ]
  • 5
  • [ 40299-87-4 ]
  • [ 14062-05-6 ]
  • [ 80-70-6 ]
  • [ 1360467-58-8 ]
  • 2-diazo-1-morpholinoethan-1-one [ No CAS ]
  • 6
  • [ 37091-73-9 ]
  • [ 80-70-6 ]
  • 1,3-dimethyl-2-(N',N',N",N"-tetramethylguanidino)-4,5-dihydro-3H-imidazolium chloride [ No CAS ]
YieldReaction ConditionsOperation in experiment
96% In tetrahydrofuran; dichloromethane; at 5 - 60℃; for 1.5h; Into 3.38 g of <strong>[37091-73-9]2-chloro-1,3-dimethylimidazolinium chloride</strong> (20 mmol; produced by Wako Pure Chemical Industries, Ltd.), 20 mL of dichloromethane and 20 mL of tetrahydrofuran (THF) were added and cooled down to 5° C., then 4.6 g of 1,1,3,3-tetramethylguanidine (40 mmol; produced by Wako Pure Chemical Industries, Ltd.) was added into that and stirred at 60° C. for 1.5 hour. After completion of the reaction, 30 mL of acetone was added to the reaction solution, and a salt precipitated was removed by filtration. The resulting organic layer was concentrated under reduced pressure to obtain 4.76 g of 1,3-dimethyl-2-(N',N',N",N"-tetramethylguanidino)-4,5-dihydro-3H-imidazolium chloride (white powder, yield: 96percent). Measurement of 1H-NMR, and a structural formula of 1,3-dimethyl-2-(N',N',N",N"-tetramethylguanidino)-4,5-dihydro-3H-imidazolium chloride are shown below. 1H-NMR (400 MHz, D2O) delta (ppm): 2.86 (6H, s), 3.04 (12H, s), 3.88 (4H, d)
96% In tetrahydrofuran; dichloromethane; at 5 - 60℃; for 1.5h; To 3.38 g of <strong>[37091-73-9]2-chloro-1,3-dimethylimidazolinium chloride</strong> (20 mmol; manufactured by Wako Pure Chemical Industries, Ltd.), 20 mL of dichloromethane and 20 mL of tetrahydrofuran (THF) were added, and the resultant was cooled to 5° C., and then 4.6 g of 1,1,3,3-tetramethylguanidine (40 mmol; manufactured by Wako Pure Chemical Industries, Ltd.) was added thereto, and the resultant was stirred at 60° C. for 1.5 hours. After the completion of the reaction, 30 mL of acetone was added to the reaction solution, and a solid precipitated was removed by filtration. The resulting organic layer was concentrated under reduced pressure to afford 4.76 g of 1,3-dimethyl-2-(N',N',N",N"-tetramethylguanidino)-4,5-dihydro-3H-imidazolium chloride (white powder, yield: 96percent). The result of 1H-NMR and the structural formula of 1,3-dimethyl-2-(N',N',N",N"-tetramethylguanidino)-4,5-dihydro-3H-imidazolium chloride are as follows. 1H-NMR (400 MHz, D2O) delta (ppm): 2.86 (6H, s), 3.04 (12H, s), 3.88 (4H, d).
  • 7
  • [ 38980-96-0 ]
  • [ 103-72-0 ]
  • [ 80-70-6 ]
  • N<SUP>2</SUP>,N<SUP>2</SUP>-dimethyl-N<SUP>4</SUP>-phenyl-6-(4-(trifluoromethyl)phenyl)-1,3,5-triazine-2,4-diamine [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 80-70-6 ]

Aliphatic Chain Hydrocarbons

Chemical Structure| 21770-81-0

A147840 [21770-81-0]

1-Methylguanidine hydrochloride

Similarity: 0.69

Chemical Structure| 4761-93-7

A194396 [4761-93-7]

Biguanidehydrochloride

Similarity: 0.58

Chemical Structure| 29166-72-1

A165559 [29166-72-1]

2-(tert-Butyl)-1,1,3,3-tetramethylguanidine

Similarity: 0.54

Amines

Chemical Structure| 21770-81-0

A147840 [21770-81-0]

1-Methylguanidine hydrochloride

Similarity: 0.69

Chemical Structure| 4761-93-7

A194396 [4761-93-7]

Biguanidehydrochloride

Similarity: 0.58

Chemical Structure| 29166-72-1

A165559 [29166-72-1]

2-(tert-Butyl)-1,1,3,3-tetramethylguanidine

Similarity: 0.54

Chemical Structure| 645-05-6

A112657 [645-05-6]

N2,N2,N4,N4,N6,N6-Hexamethyl-1,3,5-triazine-2,4,6-triamine

Similarity: 0.52

Related Parent Nucleus of
[ 80-70-6 ]

Guanidines

Chemical Structure| 21770-81-0

A147840 [21770-81-0]

1-Methylguanidine hydrochloride

Similarity: 0.69

Chemical Structure| 4761-93-7

A194396 [4761-93-7]

Biguanidehydrochloride

Similarity: 0.58

Chemical Structure| 29166-72-1

A165559 [29166-72-1]

2-(tert-Butyl)-1,1,3,3-tetramethylguanidine

Similarity: 0.54